LONDON, November 16, 2017 /PRNewswire/ --
BTG plc (LSE: BTG), the global specialist healthcare company, announces the publication of new consensus guidelines for use of Voraxaze (glucarpidase) in patients with high-dose methotrexate-induced acute kidney injury and delayed methotrexate clearance in The Oncologist.[1]
(Logo: http://photos.prnewswire.com/prnh/20150805/255981LOGO )
High-dose methotrexate, defined as a dose higher than 500 mg/m2, is used to treat a range of adult and childhood cancers, including, osteosarcoma, acute lymphoblastic leukemia, and primary central nervous system lymphoma. Acute kidney injury due to high-dose methotrexate is a serious, life-threatening toxicity that can occur in pediatric and adult patients. Voraxaze (glucarpidase) is indicated for the treatment of toxic plasma methotrexate concentrations (>1 µmol/L) in patients with delayed methotrexate clearance due to impaired renal function.
Until now, there have been no available consensus guidelines on the use of Voraxaze. An international group of experts was convened to develop a consensus guideline that was specific and evidence-based to identify the population of patients who would benefit from Voraxaze. These new guidelines recommend that "administration of Voraxazeshould optimally occur within 48-60 hours from the start of the HDMTX infusion, because life-threatening toxicities may not be preventable beyond this time point".
Dr. Peter C. Adamson of the Children's Hospital of Philadelphia, who is Chair of the Children's Oncology Group and Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, commented, "These guidelines provide a much-needed framework for how to treat patients with acute kidney injury secondary to high dose MTX. The publication will provide clinicians both practical and specific guidance on when and how to treat patients with glucarpidase to optimize the potential for benefit."
Suzanne Ward, PharmD, MBA, Senior Director of Medical Strategy for Specialty Pharmaceuticals at BTG states: "The medical community has long awaited definitive expert-consensus on how to manage delayed methotrexate elimination due to acute kidney injury, including the appropriate timeframe to intervene with glucarpidase. These guidelines provide very specific plasma methotrexate concentration thresholds as early as 24 hours following the start of methotrexate infusion, allowing clinicians to promptly identify patients at risk so that treatment occurs without delay, minimizing unnecessary over-exposure to methotrexate and toxicity progression."
The guideline provides recommendations to identify the population of patients who would benefit from glucarpidase rescue by more precisely defining the absolute methotrexate concentrations associated with risk for severe or life-threatening toxicity at several time points after the start of a high-dose methotrexate infusion. Early administration of Voraxaze may diminish the risk for serious life threatening toxicity and even death.
About BTG
BTG is a global specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of cancer, severe emphysema, severe blood clots and varicose veins, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today's most complex healthcare challenges. To learn more about BTG, please visit: btgplc.com .
For further information contact:
BTG
Andy Burrows, VP Corporate & Investor Relations
+44-(0)-20-7575-1741; Mobile: +44-(0)-7990-530-605
Stuart Hunt, Investor Relations Manager
+44-(0)-20-7575-1582; Mobile: +44-(0)-7815-778-536
Chris Sampson, Corporate Communications Director
+44-20-7575-1595; Mobile:+44-7773-251-178
FTI Consulting
Ben Atwell/Simon Conway
+44-(0)-20-3727-1000
[1] A full text version of the article can be accessed at the following link:
http://theoncologist.alphamedpress.org/content/early/2017/10/27/theoncologist.2017-0243.long
